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Redox-Mediated and Ionizing-Radiation-Induced
Inflammatory Mediators in Prostate Cancer
Development and Treatment
Lu Miao,1 Aaron K. Holley,1 Yanming Zhao,1 William H. St. Clair,2 and Daret K. St. Clair1
Abstract
Significance: Radiation therapy is widely used for treatment of prostate cancer. Radiation can directly damage
biologically important molecules; however, most effects of radiation-mediated cell killing are derived from the
generated free radicals that alter cellular redox status. Multiple proinflammatory mediators can also influence
redox status in irradiated cells and the surrounding microenvironment, thereby affecting prostate cancer pro-
gression and radiotherapy efficiency. Recent Advances: Ionizing radiation (IR)–generated oxidative stress can
regulate and be regulated by the production of proinflammatory mediators. Depending on the type and stage of
the prostate cancer cells, these proinflammatory mediators may lead to different biological consequences ranging
from cell death to development of radioresistance. Critical Issues: Tumors are heterogeneous and dynamic
communication occurs between stromal and prostate cancer cells, and complicated redox-regulated mechanisms
exist in the tumor microenvironment. Thus, antioxidant and anti-inflammatory strategies should be carefully
evaluated for each patient at different stages of the disease to maximize therapeutic benefits while minimizing
unintended side effects. Future Directions: Compared with normal cells, tumor cells are usually under higher
oxidative stress and secrete more proinflammatory mediators. Thus, redox status is often less adaptive in tumor
cells than in their normal counterparts. This difference can be exploited in a search for new cancer therapeutics
and treatment regimes that selectively activate cell death pathways in tumor cells with minimal unintended
consequences in terms of chemo- and radio-resistance in tumor cells and toxicity in normal tissues. Antioxid.
Redox Signal. 20, 1481–1500.
Introduction
Cancer is a major health issue throughout the worldand accounts for about 25% of all deaths in the United
States. Prostate cancer has accounted for *29% of newly di-
agnosed cancer cases and 9% of cancer deaths in men in 2012
(167). The common forms of treatment for prostate cancer are
surgery, radiation, chemotherapy, and hormone management
(181). Radiation therapy can be used to treat localized disease
or as part of a curative therapy to prevent cancer recurrence
after surgical removal of the primary tumor. Unfortunately,
the disease recurs and progresses to an advanced stage in as
many as 30%–40% of prostate cancer patients treated with
radiation (181). Contributing factors that influence radiation
therapy outcomes are as follows: the presence of radiation-
resistant prostate cancer cells and cancer stem cells; the
complexity of the tumor microenvironment, such as hypoxia;
increased inflammatory cytokine and growth factor secretion;
and elevated relevant receptor expression.
Consideration of the effects of radiation therapy should not
be limited to isolated cells since the entire tissue plays a role in
determining the response of individual cells to any regulatory
or damaging signals (13, 148). The localized release of radia-
tion energy generates free radicals, mainly by ionization of
water, which constitutes about 80% of cell mass, and produces
various reactive oxygen species (ROS). The ROS can then
rapidly diffuse and react with other molecules to damage
DNA, protein, and lipid targets. This ROS-mediated effect of
ionizing radiation (IR) is suspected to have caused a majority
of radiation-induced damage (13, 66). Different types of cells
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in tumor tissues are subjected to complex regulatory mecha-
nisms depending on their interactions with other cells and cel-
lular products in the microenvironment, such as interleukin-1b
(IL-1b), IL-6, IL-8, tumor necrosis factor-alpha (TNF-a), and
transforming growth factor-beta (TGF-b). Altered cytokine ex-
pression can alter many signaling pathways that converge on a
few important transcription factors, including nuclear factor
kappa B (NF-jB), activator protein-1 (AP-1), and signal trans-
ducers and activators of transcription (STATs). These tran-
scription factors also upregulate the expression of several
cytokines, such as IL-1b and TNF-a (105). Such positive feedback
loops amplify radiation- or oxidative-stress-induced inflamma-
tion, which may persist chronically (156). Because ROS play
crucial dual roles in inducing cancer development (initiation,
promotion, and progression) and maintaining metabolic ho-
meostasis, both prooxidant- and antioxidant-based agents have
been developed for cancer prevention and treatment (63, 183).
This article reviews commonly elevated cytokines and
growth factors, such as IL-6, IL-8, TNF-a, and TGF-b, as major
mediators of IR response found in prostate cancer after radi-
ation therapy, and discusses different redox signaling path-
ways and redox-sensitive transcription factors controlled by
these proteins. The biological significance of this information
can be particularly useful in understanding the development
of cancer radioresistance and improving radiation therapeutic
effects in humans.
Radiation in Prostate Cancer Treatment
IR and radiation therapy
Cancer radiotherapy is the medical use of IR to control or
kill malignant cells. For prostate cancer treatment, radiation is
most commonly given by an external source (external beam
radiotherapy), but it may also be administered by inserting
small radioactive seeds directly into the tumor (brachyther-
apy), which is appropriate for some men with early prostate
cancer (181). Delivery of a lethal dose of radiation to a tumor
lesion while minimizing damage to normal surrounding tis-
sues is one of the major challenges of radiotherapy. The ac-
curacy and precision of radiotherapy has improved as
imaging technology has improved, especially the use of 3-
dimensional conformal radiation therapy and intensity-
modulated radiation therapy (164).
External beam radiotherapy can deliver two types of ra-
diation that damage DNA and other macromolecules of
cancerous cells: photons, such as X-rays and c-rays, and
charged particles, such as protons and electrons. X-rays are
generated extranuclearly from X-ray machines whereas c-rays
are produced intranuclearly from radioactive materials.
While they differ in the source of generation, X-rays and c-
rays share the same radiophysical properties (66, 113, 148)
(Fig. 1). Direct action of IR is the interaction of radiation beams
or particles with critical target molecules in cells, such as
DNA, to cause various types of damage in DNA structure,
leading to lethal chromosome aberrations (113). Indirect ac-
tion of radiation is a multicellular effect by water radiolysis
that produces free radicals, such as hydrated electrons (e - aq),
ionized water (H2O
+ ), hydroperoxyl radical (HO2
), hydro-
gen radical (H), and hydroxyl radical (OH), which can dif-
fuse far enough to reach and damage the DNA, protein, and
lipid targets (13, 66, 113, 148). Direct action and indirect action
of IR are closely linked; for example, direct damage to DNA
by IR can induce ROS generation via histone H2AX-mediated
mechanisms that involve NADPH oxidase 1 (NOX1) and Ras-
related C3 botulinum toxin substrate 1 (Rac1) GTPase (83). To a
large extent, it is these free radicals that break chemical bonds,
produce chemical changes, and initiate the chain of events that
results in the final expression of biological damage.
It has been reported that intracellular ROS levels are
quickly increased after exposure to IR and that elevated levels
of ROS are sustained for several hours after initial IR exposure
(32, 179). NOX is responsible, in part, for a late increase in
intracellular superoxide generation after exposure to IR (32,
179). IR-induced mitochondrial dysfunction, especially de-
creased electron transport chain complex I activity, produces
a feed forward loop that contributes to persistent oxidative
stress after irradiation (198). Since the mitochondrion is the
most important energy-generating organelle, mitochondrial
dysfunction due to direct effects of IR or indirect effects me-
diated by ROS may result in alteration or adaptive responses
of metabolic pathways involved in cancer development. Free
radicals may amplify and prolong the deleterious effects of
radiation, leading to chronic oxidative stress, alteration of
multiple metabolic pathways, normal tissue injury, cell death,
and other bystander effects [reviewed in (142)].
Radioresistance: an important impediment
to prostate cancer treatment
The development of resistance to radiation is one of the
worst obstacles of prostate cancer radiotherapy. Some of the
molecular entities associated with radioresistance have been
identified in prostate cancer (71, 88, 95, 171); however, the
underlying mechanisms are still not well understood. While it
is possible to increase radiation doses to a level that ensures
complete irradiation of cancer, the use of higher doses of ra-
diation may cause unacceptable serious side effects to normal
tissues. Thus, it is important to develop strategies that can
sensitize tumor cells to radiation treatment and/or can protect
normal tissue from radiation damage.
Radiotherapy mainly induces cell death by generating ox-
idative stress, and cellular antioxidant status also affects
normal tissue injury and tumor sensitivity to radiation treat-
ment [reviewed in (71)]. Inhibiting prooxidant enzymes, such
as cyclooxygenase-2 (75), and overexpression or upregulation
of antioxidant enzymes, such as extracellular superoxide
dismutase (ECSOD) (84) and heme oxygenase-1 (200), have
been shown to protect against radiation-induced thoracic,
lung, and skin injuries (141). Radiation-resistant mice have
been shown to have higher levels of superoxide dismutase
(SOD) and catalase activities compared with radiation-
sensitive mice (69). Manganese superoxide dismutase
(MnSOD) upregulation has been implicated in adaptive re-
sponse induced by low or fractionated doses of IR, leading to
radioresistance (71, 73). MnSOD is one of the most important
antioxidant enzymes located exclusively in mitochondria, the
main source of ROS (115). The levels and activities of MnSOD
modulate cellular redox status and influence the effects of
chemotherapy and radiotherapy; therefore, MnSOD may
confer radioresistance through its antioxidant enzyme activ-
ity. Our previous studies have demonstrated that selective
inhibition of RelB-induced MnSOD after irradiation can sen-
sitize prostate cancer cells to radiation treatment (71, 79),
confirming the importance of MnSOD in radioresistance.
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Depending on the level of tolerance to oxidative stress,
different cancer cell types may exhibit an opposite response to
ROS elevation. For example, the anticancer drug 2-methoxy-
estradiol (2-ME) is associated with upregulation of MnSOD
as an adaptive response that protects pancreatic cancer cells
from increased ROS (202). In contrast, 2-ME can sensitize
radioresistant MCF-7/FIR breast cancer cells by activating
apoptosis, arresting the cell cycle, and further enhancing
radiation-induced ROS (152). Therefore, applying redox-
modulating reagents, such as ascorbate (49), arsenic trioxide
(34), selenite (76), or a metalloporphyrin antioxidant mimetic
(MnTE-2-PyP) (112), in combination with IR can either in-
crease the cell-killing effect of IR or protect against radiation-
induced oxidative stress to surrounding normal tissues.
The neuroendocrine differentiation (NED) of prostate
cancer cells is closely correlated with radioresistance (43, 185).
In the prostate gland, neuroendocrine (NE) cells are < 1% of
total epithelial cells; however, the number of NE-like cells
increases in advanced prostate cancer (129). Fractionated IR
can induce NED in the LNCaP prostate cancer cell line by
activation of the cAMP response element binding protein
(CREB) and cytoplasmic sequestration of activating tran-
scription factor 2 (ATF2) (43). NE-like cells can dedifferentiate
to a proliferating state, which may contribute to tumor re-
currence (43, 44). Interestingly, by utilizing LNCaP cell clones
with stably overexpressed MnSOD with lower superoxide
levels and higher H2O2 levels, Quiros-Gonzalez et al. showed
that MnSOD upregulation was sufficient to drive NE differ-
entiation, resulting in androgen independence and cell sur-
vival in prostate cancer cells (145). It has been proposed that
the balance between O2
 - and H2O2 can determine pathways
that drive the NED process (145). Thus, it is conceivable that
MnSOD might affect NED by modulating the rate of H2O2
production and the balance between O2
 - and H2O2. Further
investigation of the roles of MnSOD in regulating prostate
cancer cell NED and the significance of NED in prostate
cancer radioresistance and recurrence may lead to discoveries
that can be explored to overcome radioresistance.
ROS and Prostate Cancer
Reactive species, which include ROS and reactive nitrogen
species (RNS), are categorized into two groups: free radicals
that contain one or more unpaired electrons, such as super-
oxide (O2
 - ), OH, and nitric oxide (NO), and nonradicals,
such as hydrogen peroxide (H2O2). Biological organisms are
FIG. 1. Electromagnetic spectrum of radiation and medical use of ionizing radiation (IR). Direct action of IR leads to
damages in DNA structure. Indirect action of radiation results from water radiolysis, which produces free radicals that can
diffuse far enough to reach and damage the DNA.
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able to maintain a delicate redox homeostasis because they
contain a complex intracellular ‘‘redox buffer’’ network, in-
cluding both enzymatic and nonenzymatic antioxidants. The
major enzyme defense system against ROS includes SOD,
catalase, glutathione peroxidase, peroxiredoxin, and gluta-
thione S-transferase (GST) (74). In addition to these antioxi-
dant enzymes, small thiol-containing peptides, such as
glutathione (GSH), glutaredoxin, and thioredoxin (Trx) sys-
tems, also help to scavenge ROS and maintain appropriate
redox homeostasis (157).
The redox status (oxidizing/reducing conditions) of cells
can regulate various transcription factors/activators, such as
AP-1, NF-jB, and p53, thereby influencing target gene ex-
pression and modulating cellular signaling pathways. Re-
quisite levels of ROS and RNS must be present for normal
physiological function of living organisms (177). An increase
in production of reactive species and/or a decrease in anti-
oxidants can lead to oxidative stress, which can damage
DNA, inhibit cellular enzyme activities, and induce cell death
through activation of kinases and caspase cascades (154).
Oxidative stress resulting from an imbalance between
prooxidants and antioxidants that favors the former is be-
lieved to play a critical role in prostate carcinogenesis and
prostate cancer progression [reviewed in (64)].
Sources of ROS
ROS derived from incomplete reduction of oxygen can be
produced either endogenously (e.g., mitochondria respira-
tion) or exogenously (e.g., IR) (80, 125) (Fig. 2). The most im-
portant endogenous source of ROS is the mitochondrial
electron transport chain (ETC). The electrons that leak from
some components of mitochondrial ETC lead to a one-electron
reduction of O2 and generation of superoxide radicals (O2
 - ).
Superoxide can be dismutated by SOD to yield hydrogen
peroxide and O2. In the presence of transition metal ions, es-
pecially iron ions, hydrogen peroxide is subsequently con-
verted through Fenton and Haber-Weiss reactions to a
hydroxyl radical, which is the most toxic form of ROS, leading
to various types of lipid peroxidation, protein modification,
and particularly oxidative DNA damages, such as 8-hydroxy-
deoxyguanosine (148). Somatic mutations in the mitochondrial
FIG. 2. Scheme of cellular reactive oxygen species (ROS) generation and the antioxidant system. ROS generated from
extracellular or intracellular sources can damage nuclear and mitochondrial DNA. Various transcription factors, such as nuclear factor
kappa B (NF-jB), p53, activator protein-1 (AP-1), signal transducers and activators of transcription (STAT)3, Nrf2, HIF-1a, Sp1, PPARc,
and Ref1 are modulated by ROS. Examples of extracellular sources of ROS: radiation, carcinogens, inflammation, and hypoxia.
Intracellular sources of ROS: ETC, electron transport chain; XO, xanthine oxidase; LPX, lipoxygenase; P450, cytochrome P450; COX,
cyclooxygenase. Antioxidant system: MnSOD; Cu/ZnSOD; ECSOD, extracellular superoxide dismutase; GSH, glutathione; GPx,
glutathione peroxidase; Prx, peroxiredoxin; GR, glutathione reductase; TrxR, thioredoxin reductase; TRXox, oxidized thioredoxin;
TRXre, reduced thioredoxin; HIF-1a, hypoxia-inducible factor 1-alpha; PPARc, peroxisome proliferator-activated receptor gamma.
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genome are relatively frequent events in prostate cancer.
Compared with nuclear DNA, mitochondrial DNA (mtDNA)
is more susceptible to radiation-induced loss of integrity due,
in part, to the lack of protective histones, an inefficient
DNA repair system, and continuous exposure to the mutagenic
effect of ROS (187), which is exacerbated by GSH depletion in
mitochondria (120). ROS-induced mtDNA damage can alter
polypeptides encoded by mtDNA for respiratory complexes,
resulting in additional decreased electron transfer activity
and increased ROS generation, thereby establishing a vicious
cycle of oxidative stress (102) and decline in mitochondria
energy production after initial oxidative damage of mtDNA
(101). Mitochondrial dysfunction that causes persistent oxida-
tive stress may contribute to radiation-induced genomic in-
stability (198).
ROS can also be generated by other enzymes, such as
xanthine oxidase, membrane-associated NOX, and cyto-
chrome P450 in endoplasmic reticulum, and oxidases in per-
oxisomes (97). The association of NOX enzymes with prostate
cancer growth and malignant phenotypes has been exten-
sively reviewed (86, 98).
ROS and prostate cancer progression
Increased oxidative stress plays a significant role in sev-
eral physiological/pathological situations, such as aging and
aging-associated diseases. Prostate cancer is closely associ-
ated with aging as it occurs frequently in older men. Prostate
cancer cells generally have a higher level of oxidative stress
compared with normal prostate cells, and the level of oxi-
dative stress is associated with prostate cancer occurrence,
recurrence, and progression (10, 21, 98). It has been demon-
strated that, at an early stage of cancer development, tumor
cells are exposed to high oxidative stress, in part due to in-
hibition of various antioxidant enzyme activities (Fig. 3).
Lower levels of antioxidant enzymes, such as MnSOD, cop-
per/zinc SOD, and catalase (10, 21) and defects in several
classes of GSTs (22) have been observed repeatedly in prostate
adenocarcinoma compared with benign prostate cells and
tissues. However, after cancer has progressed, ROS partially
render cancer cells more dependent on the function of anti-
oxidant enzymes, such as SODs, to protect against damages
caused by increased levels of superoxide radicals (115). Our
laboratory has provided in vivo evidence and has proposed a
model for the underlying molecular mechanism by which p53
differentially regulates MnSOD expression between early and
advanced stages of cancer (46).
The protein levels of some antioxidant enzymes and sig-
naling molecules are associated with cellular redox status. The
proteins play a more dominant role when activation/inhibi-
tion of enzymatic activity and redox modification during re-
dox signaling, or in response to cellular redox change in
specific cellular compartments, occurs (Table 1). For example,
it has been suggested that redox-sensitive molecule Trx1
functions as a protective cellular antioxidant and its upregu-
lation protects cancer cells from oxidative stress (122). How-
ever, despite a significant increase in its protein level, oxidation
of nuclear Trx1 resulted in a loss of antioxidant activity, which
clearly demonstrates that when redox imbalance occurs,
prostate cancer cells adapt to oxidative stress (161). Therefore,
characterization of redox-sensitive protein structure and cel-
lular localization, identification of potential redox modifica-
tions based on structure information and modeling strategies,
and investigation of different functions before and after mod-
ification will provide insightful knowledge of cellular redox
status at each stage of cancer development.
Based on the biomedical property of increased ROS and
altered redox status in cancer cells, many avenues of research
have been proposed to modulate the unique redox regulatory
mechanisms of cancer cells for therapeutic benefits (183).
FIG. 3. Role of oxidative
stress in cancer development
and radioresistance. IR-
induced genomic instability
and oxidative stress are clo-
sely related to each other.
Many human cancer cells
harbor low levels of antioxi-
dants at early stages of a tu-
mor, whereas cancer cells
may eventually become re-
sistant to radiation treatment
and/or chemotherapy and
possess high levels of antiox-
idants at advanced stages of a
tumor. With cancer develop-
ment, tumor cells are contin-
uously facing increased
oxidative stress and risk of
genomic instability.
RADIATION-INDUCED INFLAMMATORY MEDIATORS IN PROSTATE CANCER 1485
Mitochondrial ROS have been shown to promote proin-
flammatory cytokine expression (27) and NLRP3 inflamma-
some activity (174). Blocking androgen-induced ROS
production by inhibiting polyamine oxidase could delay
prostate cancer progression and prolong survival of animals
when spontaneous prostate cancer develops (14). A highly
oxidizing condition is strongly cytotoxic and is the primary
mechanism for tumor cell killing by radiation therapy and
some chemotherapeutics, such as Taxol and Adriamycin.
Since tumor cells are under more oxidative stress and normal
cells usually carry higher redox-buffering capacity, specific
mild prooxidants, such as parthenolide, have been shown to
be redox-modulating reagents capable of selectively pushing
tumor cells beyond their tolerance to oxidative stress and
sensitizing cancer cells to radiation-induced cell killing (178).
ROS are not only involved in radioresistance but also are
implicated in prostate cancer progression and castration re-
sistance. Growth and proliferation of castration-resistant
prostate cancer are mediated by gain-of-function changes in
the androgen receptor (AR) and AR reactivation. MnSOD
downregulation is directly responsible for AR reactivation in
prostate cancer and occurs through an ROS-mediated mech-
anism (163). Shiota et al. have extensively reviewed both the
effects of AR signaling on oxidative stress and the effects of
oxidative stress on AR signaling in the context of prostate
cancer, especially castration-resistant prostate cancer (165).
Castration-induced oxidative stress may promote AR over-
expression through transcription factor Twist1 over-
expression, which may result in a gain of castration resistance
(166). Thus, modulating redox status to sensitize cells and
overcome radioresistance may result in castration resistance,
which diminishes the therapeutic benefits of redox modula-
tion. Thus, the stage of prostate cancer development and AR
signaling must be carefully determined before introducing
redox intervention strategies.
Role of ROS in the interaction between
stroma and prostate cancer cells
It is becoming increasingly clear that the microenvironment
is crucial to prostate cancer cell survival, progression, me-
tastasis [reviewed in (20)], and resistance to chemotherapy
and/or radiotherapy. Redox status within such a microenvi-
ronment is complicated at all stages of prostate cancer de-
velopment, due to the considerable heterogeneity of the
cellular composition of stroma and tumors. IR generates
highly reactive free radicals, and it has been well documented
that stromal components, such as cancer-associated fibro-
blasts (CAFs), tumor-associated macrophages (TAMs), and
endothelial cells, enhance oxidative stress, which promotes
tumor progression (2, 50).
As the most abundant cell type in the microenvironment of
solid tumors, fibroblasts are particularly prominent in prostatic
carcinoma (Fig. 4). The origin of CAFs and their significance in
determining cancer aggressiveness have been elegantly dem-
onstrated previously (109, 134). Cunha and colleagues have
shown that CAFs contribute to prostate tumor growth and
metastatic potential. Human prostatic CAFs grown using ini-
tiated human prostatic epithelial cells dramatically stimulated
the growth and altered histological characteristics of the epi-
thelial cell population. However, this effect was not observed
when normal prostatic fibroblasts were grown using initiated
epithelial cells under the same experimental conditions (134).
It has been observed that ROS formation increased imme-
diately after irradiation and continued for several hours, re-
sulting in the production of 8-oxoguanine, which is a product of
oxidative DNA damage (132). Oxidative damage in DNA is
repaired mainly via the base excision repair (BER) pathway (42).
The BER pathway is initiated by removal of the base by DNA
glycosylases, leaving an intact abasic (AP) site. Subsequently,
AP endonuclease 1 (APE1/Ref1) nicks the damaged DNA
strand upstream of the AP site, creating a 3¢-hydroxyl terminus
and a 5¢-deoxyribose phosphate group flanking the gap (172).
APE1/Ref-1 (APE1) possesses not only DNA repair functions
but also transcriptional regulatory activities, controlling cellular
response to oxidative stress (180). APE1 has been identified as a
protein with nuclear redox activity, inducing the DNA binding
activity of several transcription factors, such as AP-1, NF-jB,
hypoxia-inducible factor-1a, p53, Myb, and the ATF/CREB
family [reviewed in (180)]. Thus, while IR-induced ROS lead to
oxidative DNA damage, their repair can also contribute to
cellular redox status, at least in part, through APE1/Ref-1
functions.
Due to diffusibility and abundance, multiple ROS and in-
flammatory mediators associated with aging, infection, or IR
exposure may provide a permissive environment for cancer
development. Compelling experimental and clinical evidence
indicates that ROS-mediated stromal–epithelial interactions
in both normal and malignant prostatic environments in-
volve a number of soluble factors and their corresponding
receptors (37). ECSOD plays predominant roles in scavenging
superoxide in the extracellular space where redox state
Table 1. Roles of MnSOD Expression or Activity and MnSOD-Regulated Cellular
Redox Status in Different Stages of Tumor Development
Tumor development Normal cells Early stage of cancer Advanced stage of cancer
MnSOD level or activity High Low Very high
Yprooxidant [prooxidant [prooxidant
Cellular redox status [antioxidant Yantioxidant [antioxidant
Low oxidative stress Modest oxidative stress High oxidative stress
Sensitivity to ROS + + + + + +
Implications in radiotherapy
Protect normal cells from
oxidative insults such as
radiation by inducing
adaptive responses
Promote radiation-mediated
cell killing due to low level
of antioxidant capacity
Protect tumor cells from
radiation and modulate
neuroendocrine-like
differentiation leading to
radioresistance
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regulates intracellular signaling or tumor growth. ECSOD-
derived H2O2 can promote vascular endothelial growth factor
(VEGF) signaling in caveolin-enriched lipid rafts and stimu-
late endothelial cell migration and proliferation through oxi-
dative inactivation of protein tyrosine phosphatases (PTPs),
such as density-enhanced protein tyrosine phosphatase-1
(DEP-1) and PTP1B (135). VEGF is critical for not only an-
giogenesis but also prostate-cancer-mediated osteoblastic
activity (93). IR modulates VEGF expression through multiple
mitogen activated protein kinases (MAPK)–dependent path-
ways (137) and enhances glioma cell motility through vas-
cular endothelial growth factor receptor 2 (VEGFR2) signaling
pathways (87). Since prostate cancer cells lack expression of
specific VEGF receptors, especially VEGFR2, IR-induced
VEGFs are more likely to promote prostate cancer progression
indirectly through their functions in stromal cells, in particu-
lar, endothelial cell survival, and as a chemotactic agent
within the tumor microenvironment (93). In addition to en-
dothelial cells, CAFs can also exert their cancer-promoting
roles through release of growth factors, such as TGF-b and
epidermal growth factor (EGF), as well as chemokines (2).
Oxidative-stress-dependent monocarboxylate transporter 4
expression in CAFs is closely involved in stromal–epithelial
lactate shuttling (190). According to a recently proposed
model, an increase of ROS in CAFs drives tumor-stroma co-
evolution, DNA damage, and aneuploidy in cancer cells (109).
Pavlides et al. have provided detailed information on how
CAFs accelerate tumor growth and metastasis via oxidative
stress, mitophagy, and aerobic glycolysis (138). The multiple
roles of ROS in these new metabolic coupling interactions and
models suggest that certain redox-modulation-based thera-
peutic methods can be helpful when used in combination with
traditional radiotherapy in prostate cancer treatment.
The radiation-induced bystander effect, mediated through
gap junctions and inflammatory responses, is defined as the
response of cells to their irradiated neighbors (142). Many
types of cancer-infiltrating immune cells, such as macro-
phages, dendritic cells, and T cells, are important stromal
components of a prostate tumor as well as being prominent
bystander targets of radiotherapy. More information on the
mechanisms by which IR influences tumor-associated im-
mune responses and various immune cells to secrete different
inflammatory mediators appear in recent reviews (38, 123).
Thus, activated immune cells are not limited to induction of
antitumor immunity; they are also involved in creating an
immunosuppressive and prooxidant network that promotes
tumor progression and facilitates immune evasion. Since tu-
mor cells are often under higher oxidative stress with dis-
regulated and/or less adaptive redox buffering capacity than
their normal counterparts, tumor cells are probably less able
to cope with additional incremental increases in oxidative
stress than normal cells are, which can be explored to enhance
antitumor immunity while minimizing the possibility of un-
intended tumor progression and evasion.
FIG. 4. Radiotherapy-induced cell killing and unintended effects on tumor stromal components leading to inflamma-
tory mediator secretion. Inflammatory mediators induced by IR include epidermal growth factor (EGF), fibroblast growth
factor (FGF), interferon-c (IFN-c), transforming growth factor-beta (TGF-b), interleukin-6 (IL-6), tumor necrosis factor-alpha
(TNF-a), and IL-8. Both radiation treatment and IR-induced inflammatory mediators increase ROS levels within a tumor
microenvironment, which contributes to radioresistance and recurrence of cancer.
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Radiotherapy-Induced Inflammatory
Mediator Secretion
When cells are exposed to IR, DNA damage generated from
either direct or indirect effects of IR induces a multicellular
program through a variety of signaling pathways to start DNA
repair and prevent the proliferation of damaged cells. Such
programs are usually mediated by soluble factors composed of
cytokines, growth factors, and chemokines, which perform
functions in both tumors and stroma to determine the fate of
affected cells (13). IR exposure commonly induces stromal cells,
especially CAFs, into a senescence-like phenotype in an altered
tumor microenvironment. The so-called senescence-activated
secretory pathways in senescent stromal fibroblasts generate
an inflammatory environment through the secretion of proin-
flammatory cytokines and proteases (50). These soluble factors
can exert paracrine or autocrine functions mediated by their
respective receptors or interactive partners to promote prostate
cancer progression and to create a continuous loop that pushes
prostate cancer to a more aggressive state.
Chronic inflammatory mediator secretion associated with
aging has been involved in the etiology and progression of
prostate cancer. A chronic inflammatory microenvironment
leads to an increased fraction of epithelial cells that proliferate
in local atrophy lesions, an event called proliferative inflam-
matory atrophy (PIA) (149). PIA may progress to high-grade
intraepithelial neoplasia and prostate cancer (96). That a re-
lationship exists between a chronic inflammatory microenvi-
ronment and prostate cancer is gaining wide acceptance (39,
67). The evidence that the microenvironment is altered as a
result of radiotherapy, especially that various types of cyto-
kines are generated, has been elegantly reviewed (13, 142).
There are many types of mediators induced by IR (13), in-
cluding EGF (45), fibroblast growth factor (13), interferon-c
(54), TGF-b (78), proinflammatory cytokines IL-6 (35), TNF-a
(201), the chemokine IL-8 (128), and others (111). A range of
studies has shown that a clear difference exists in the level of
circulating cytokines in prostate cancer patients compared
with normal or benign controls and changes in levels of cir-
culating cytokines after radiation exposure and/or androgen
deprivation therapy (26). For the purpose of brevity, we will
only highlight the signaling pathways mediated by IL-6, IL-8,
TNF-a, and TGF-b induced by IR, as well as their implications
in prostate cancer malignancy and their potential significance
in radiotherapy of prostate cancer.
Interleukin-6
IL-6 is a multifunctional cytokine that signals through a
cell-surface type 1 cytokine receptor complex composed of
the ligand-binding protein of IL-6Ra (also called CD126) and
the signal-transducing component gp130 (CD130) (62). An-
other type of receptor for IL-6 is a soluble IL-6 receptor
(sIL-6R) that lacks a membrane-signaling domain but can
bind with IL-6 and then with the membrane receptor b chain
(gp130) to mediate the intracellular signaling pathways (153).
IL-6 mainly activates the Janus kinase ( JAK)/STAT3 signaling
pathway (110), but it also participates in the MAPK and
phosphatidyl inositol 3-kinase (PI3K)/Akt pathways to in-
fluence a wide range of biological activities in tumor cells
(150). IL-6 also acts as an autocrine and/or paracrine prolif-
erative factor in prostate cancer cell lines (133). IL-6 treatment
not only stimulates the IL-6 autocrine loop but also activates
insulin-like type I growth factor receptor (IGF-1R) signaling.
This STAT3-mediated cooperation between IL-6 signaling
and IGF-1R signaling in the prostate plays a critical role in
facilitating prostate malignancy and epithelial–mesenchymal
transition (EMT). STAT3 has been shown to promote onco-
genesis in human cancer through Src oncogene transforma-
tion of STAT3 cells (199). In addition to its classical role in the
nucleus, STAT3 modified by serine phosphorylation aug-
ments oxidative phosphorylation in mitochondria and sup-
ports cellular transformation by the oncogene Ras (58).
Considering the different cellular localization of STAT3 im-
plicated in intracellular energy metabolism and a variety of
redox-sensitive genes, it will be interesting to investigate mi-
tochondrial functions and cellular transformation under IR-
induced IL-6 activation (Fig. 5).
Different cell types, such as B and T cells, macrophages,
monocytes, fibroblasts, and certain tumor cells, can synthesize
IL-6 (92), which regulates various cellular functions, including
immune response, proliferation, apoptosis, angiogenesis, and
differentiation (41). Several clinical studies have reported that
elevated serum levels of IL-6 and sIL-6R are associated with
metastasis and castration resistance, suggesting that IL-6 corre-
lates with prostate cancer progression and patient morbidity (1,
25, 126). Most clinical data support the biological role of the IL-6
pathway in prostate cancer, especially in an advanced castra-
tion-resistant prostate cancer patient where the significance of
the IL-6 pathway is mediated by crosstalk between IL-6 and the
AR pathway (9). Under androgen deprivation conditions, IL-6 is
able to promote intracellular synthesis of androgens in the
prostate (36), resulting in AR activation and upregulation of AR-
targeted prostate specific antigen (PSA) expression, via STAT3
and MAPK signaling pathways (9), as well as an androgen en-
hancer region within the human PSA promoter (184).
Even though increased IL-6 may indicate the presence of an
advanced prostate cancer tumor in a patient or in in vivo ex-
periments, some in vitro results that support the significance
of the IL-6 pathway in the growth of prostate cancer cells are
still controversial. IL-6 can act as either a growth inducer (144)
or inhibitor (70) in androgen-dependent LNCaP cells (9). It is
possible that IL-6-induced growth arrest may be associated
with NED (175). The presence of NE-like cells has been cor-
related with a radioresistant phenotype and an unfavorable
prognosis (43, 185).
IL-6 signaling is tightly regulated by several negative
feedback inhibitors, including suppressors of cytokine sig-
naling, Src-homology 2 containing protein tyrosine phos-
phatases, and protein inhibitors of activated STATs (40, 99).
The mechanisms by which these inhibitors regulate IL-6 in-
tracellular signaling pathways have been reviewed previ-
ously in detail (40). Since IL-6 also plays an inhibitory role in
prostate cancer cells depending on signaling crosstalk and the
difference between the cancer and normal cells in redox status
and adaptive response to oxidative stress may influence the
signaling crosstalk, blocking IL-6 with antibody or signaling
inhibitors may instead promote prostate cancer progression.
Thus, it is necessary to identify the role of IL-6 signaling in
specific situations before applying anti-IL-6-related therapy.
Interleukin-8
IL-8, also known as CXCL8, is a chemoattractant chemo-
kine. IL-8 is usually associated with inflammation that
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predisposes cells to produce different chemokines for malig-
nant transformation or progression (170). IL-8 secretion is
increased by oxidative stress from either intracellular or ex-
tracellular sources. IL-8 can stimulate the recruitment of in-
flammatory cells, which further elevates oxidant stress
mediators, thereby making IL-8 a key parameter in localized
inflammation (186). Two cell-surface G protein-coupled re-
ceptors, CXCR1 and CXCR2 (72), are responsible for the
binding of IL-8 and regulating target gene expression through
downstream signaling pathways, such as activation of serine/
threonine kinases, protein tyrosine kinases, and Rho-GTPases
(189). Depletion of CXCR1 leads to inhibition of IL-8-mediated
androgen-independent tumor growth by increasing proa-
poptotic proteins and decreasing antiapoptotic proteins (160).
Increased IL-8 expression is associated with both a high
Gleason score and a tumor pathologic stage (56). Elevation of
IL-8 expression has been linked to various markers of the
progression of prostate cancer up to an advanced stage, such
as castration resistance, metastasis, and enhanced angiogen-
esis in vitro (7, 159), in vivo (7, 197), and in human patients (30).
It has been shown that IL-8 signaling, which is endogenous
and induced by a TNF-related apoptosis-inducing ligand, can
modulate the extrinsic apoptosis pathway in prostate cancer
cells through direct transcriptional regulation of c-FLIP, an
endogenous caspase-8 inhibitor, and reduce the propensity of
prostate cancer cells to undergo apoptosis (194). Therefore,
inhibiting IL-8 signaling may be a promising strategy to
sensitize advanced prostate cancer to chemotherapy. The re-
duction of intrinsic IL-8 potentiates ansamycin-based heat
shock protein 90 cytotoxicity by several mechanisms, in-
cluding inhibition of IL-8-induced NF-jB activity (158), cell
cycle arrest at the G1/S boundary, and increased spontaneous
apoptosis as well as enhancement of the efficacy of multiple
chemotherapeutic drugs, such as Docetaxel, Staurosporine,
and Rapamycin (168).
There are currently seven known CXC chemokine receptors
in mammals, named CXCR1 through CXCR7. Various types
of crosstalk exist between different chemokine-mediated sig-
naling pathways due to remarkable redundancy within che-
mokines with multiple chemokine bindings to similar or the
same receptor(s) and multiple receptors binding with similar
or the same chemokine(s) (53). It has been shown that IL-8 can
upregulate CXCR7 expression and the ligand-independent
functions of CXCR7, which usually binds to CXCL11 and
FIG. 5. IL-6-mediated Jak-STAT3 signaling pathway. IL-6 signals through a cell-surface type 1 cytokine receptor complex
composed of the ligand-binding protein of IL-6Ra and the signal-transducing component gp130 (glycoprotein of 130 kDa).
IL-6 can also bind to soluble IL-6 receptor (sIL-6R), which lacks a membrane-signaling domain, and then with gp130 to
mediate Jak phosphorylation and activation. Activated Jak family tyrosine kinases further phosphorylate STAT3, which in
turn translocate to the nucleus and regulate target gene transcription. Many types of growth factors, such as EGF, vascular
endothelial growth factor (VEGF), FGF, and insulin-like type I growth factor (IGF), can aggregate with respective receptors
and activate STAT3 signaling pathways.
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CXCL12 ligands to promote the growth, proliferation, and
angiogenesis of prostate cancer cells by increasing epidermal
growth factor receptor (EGFR) and ERK1/2 phosphorylation
(169). Therefore, the effects of IL-8/IL-8 receptor signaling
pathways in prostate cancer progression and radiation sen-
sitivity may be orchestrated by communication and/or in-
teraction with many chemokines and their receptors, such as
CXCR1–7.
The correlation between IL-8 signaling and AR signaling
pathways has been reviewed previously (170, 189). Proteomic
data illustrate that the androgen-stimulated LNCaP cells have
increased expression of IL-8 (55), which is dependent on AR.
Additionally, IL-8 signaling also increases AR expression and
alters the distribution and transcriptional activation of AR,
leading to increased expression of AR-targeted genes (159).
Since the transition of prostate cancer to an androgen-
independent state is partially due to IL-8-signaling-induced
AR activation, targeting IL-8 expression and signaling path-
ways may significantly enhance the efficacy of androgen ab-
lation therapy.
In addition to establishing the importance of IL-8 in de-
veloping chemoresistance (193), our laboratory found that the
RelB-mediated NF-jB alternative pathway plays a crucial role
in IL-8 upregulation, which enhances the radioresistance of
prostate cancer cells (196). This result is consistent with the
observation that RelB promotes prostate cancer progression
and radioresistance (197). The relationship of the NF-jB
pathway, increased antioxidant capacity, and resistance to
radiation treatment in many tumor cell types has been well
documented (61, 147). It has been demonstrated, and re-
viewed, that RelB regulates MnSOD gene expression and the
radioresistance of prostate cancer cells (71, 79). Selective in-
hibition of the RelB-mediated NF-jB alternative pathway can,
to a remarkable degree, sensitize prostate cancer cells to IR-
induced killing (71). Thus, it will be interesting to investigate
the relationship of radiosensitizing effects of IL-8 signaling
blockage with either inhibitors of IL-8 receptors or monoclo-
nal antibodies against IL-8. This strategy may synergistically
facilitate the killing of castration-resistant and/or radiation-
resistant prostate cancer cells.
Tumor necrosis factor-alpha
TNF-a is synthesized as a 26 kDa (233 amino acids)
membrane-bound pro-peptide (pro-TNF) and is released as a
17 kDa soluble polypeptide (157 amino acids) after cleavage
by the TNF-converting enzyme (119). The action of TNF-a is
mediated by two distinct receptors, TNF-receptor I (55 kDa,
TNFRI) (106), which mediates the majority of TNF-a biologi-
cal activities, and receptor II (75 kDa, TNFRII) (173), with both
having an affinity for TNF-a in human tissues. An imbalance
between prosurvival and apoptosis signals by TNF-a-initiated
signaling pathways (Fig. 6) has been implicated in malig-
nancies of the colon (52), ovary (151), breast (149), and pros-
tate (117).
TNF-a is one of the central factors involved in stress re-
sponses, including response to radiation exposure, because of
its ability to induce rapid hemorrhagic necrosis via selective
destruction of tumor blood vessels and generate specific T-cell
antitumor immunity (100). Antagonists of TNF-a action have
been developed for the treatment of rheumatoid arthritis and
other inflammatory diseases (11). When present chronically in
the tumor microenvironment, TNF-a is a major mediator of
cancer-related inflammation. In addition to maintaining ho-
meostasis of the immune system, inflammation, and host
defense, TNF-a also plays paradoxical roles in cancer pro-
motion and progression pathways leading to activation of
NF-jB and AP-1 transcription factor complexes [reviewed by
Balkwill (11)]. Circulating TNF-a is normally not detectable in
healthy individuals but can be detected in some cancer pa-
tients (25, 117). While it remains to be determined whether
TNF-a elevation in prostate cancer patients is the cause or
consequence of cancer development and progression, a rela-
tively consistent association between increased TNF-a and
cachexia in patients with prostate carcinoma (127, 140) has
been determined, and it is one of the most devastating con-
ditions of late stages of cancer. TNF-a plays multiple roles in
changes related to cancer cachexia, such as altered nitrogen
metabolism associated with cachexia (3), blockage of muscle
differentiation associated with muscle tissue regeneration
(29), and activation of transcription factors NF-jB and AP-1 to
increase proteolysis (182) [reviewed in (8)].
TNF-a is often produced in response to oxidative stress and
it acts, at least in part, by causing oxidative stress in its target
cells. Mitochondria are the primary generators of ROS, which
contribute to the TNF-a-initiated signaling pathway (81). TNF-
a-induced ROS, which can be inhibited by mitochondrial-
specific MnSOD overexpression, may oxidize and inhibit c-Jun
N-terminal Kinase (JNK)-inactivating phosphatases, and sus-
tained JNK activation is required for cytochrome c release
and caspase 3 cleavage as well as necrotic cell death (81). NOX
activation is involved in TNF-a-induced ROS production, de-
pending on cell type and the extent of TNF-a exposure (90, 104).
It has been shown that acute TNF-a exposure induces rapid
(within 5 min) p47phox phosphorylation and increases p47phox-
TNF-a receptor-associated factor 4 association and membrane
translocation, which further mediates p47phox-p22phox complex
formation, leading to NADPH-dependent O2
 - production
(104). The binding of TNF-a to TNFR1 can activate NOX1 or
NOX2 to generate ROS in early endosome (131). During
TNF-a-induced necrotic cell death, Nox1 is activated by
forming a complex with TRADD (TNF-receptor-associated
protein with death domain), RIP1 (Receptor Interacting Pro-
tein 1), and Rac1 (90). This NOX-dependent redox-regulated
mechanism plays a key role in TNF-a-induced necrotic
cell death.
Most studies referenced before used a relatively high dose
of TNF-a to induce an acute and pro-cell death response.
However, chronic elevation of TNF-a at a relatively low level
can result in cytoprotection, which is related to increased
levels of antioxidant, antiapoptotic, and other defense pro-
teins, such as thioredoxins and MnSOD. Increased mito-
chondrial ROS production induced by TNF-a leads to
activation of nuclear genes, especially NF-jB. In human and
mouse ovarian cancer, TNF-a maintains TNFR1-dependent
IL-17 production by CD4 + cells, which leads to myeloid cell
recruitment into the tumor microenvironment and enhances
tumor growth (31). TNF-a can be produced when NF-jB is
activated and TNF-a is also an important stimulus of NF-jB
signaling and additional cytokine production. The NF-jB
signaling pathway is critical in supporting cancer-related in-
flammation and malignant progression as well as maintaining
the immunosuppressive phenotype of TAMs (65). TNF-a may
play a role in the initiation of an androgen-independent state
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in prostate cancer through its ability to inhibit AR sensitiv-
ity (118). The interplay of NF-jB and B-myb contributes to
negative regulation of AR expression by TNF-a (94). Im-
munohistochemistry results show that nuclear localization of
NF-jB family member p65 is associated with PSA relapse, the
first sign of prostate cancer recurrence, while cytoplasmic
expression does not (47). Our laboratory demonstrated that
the RelB-mediated alternative NF-jB pathway is involved in
prostate cancer aggressiveness and radiation resistance (71,
79, 197). TNF-a functions as a potent inducer of the NF-jB
signaling pathway and mediates the crosstalk between the
classical and alternative NF-jB signaling pathways, as well as
interactions with AR (according to our unpublished data).
Thus, it is important to investigate in prostate cancer the ef-
fects of TNF-a production after chemo/radiotherapy and
the potential influences of TNF-a on the activation of the
RelB-mediated alternative NF-jB pathway.
The expression and activation of several genes and kinases,
such as cyclooxygenase-2, Cyclin D1, the Bcl-2 family, survi-
vin, Akt, and EGFR, are regulated by NF-jB in various tumor
cells (103). The therapeutic potential and benefit of targeting
NF-jB in cancer and the possible complications and pitfalls
associated with NF-jB modulation have been reviewed and
explored (15). Inhibition of NF-jB has been proposed as a
means to treat cancer or to overcome chemoresistance and
radioresistance in cancer therapy (103). Inhibition of IR-
induced NF-jB activation sensitizes Ki-Ras transformed
prostate epithelial cells (267b1/K-Ras) to IR (88). Selective
inhibition of RelB nuclear activation and downregulation of
RelB-targeted MnSOD gene expression improve IR-induced
killing of PC3 cells (71).
Novel strategies have been proposed to target TNF-a-
mediated signaling for treatment of human prostate cancer.
For example, Gambogic acid can inhibit TNF-a-induced in-
vasion of human prostate cancer PC3 cells in vitro by in-
hibiting the PI3K/Akt and NF-jB pathways (107). TNF-a
induces MnSOD expression, which mediates delayed radio-
protection (124) through an NF-jB binding site located within
the second intron of the sod2 gene (115). The natural com-
pound curcumin acts as a potent radiosensitizer in PC3 cells
FIG. 6. TNFa-regulated major cellular signaling pathways. Binding of TNFa to TNFR1/2 leads to the rapid phosphory-
lation of the NF-jB, ERK, p38, and JNK pathways, and activates a group of transcription factors, such as NF-jB, Elk1, and
AP-1, in the nucleus. In addition to these pro-survival pathways, TNF-a can induce apoptosis through receptor-mediated
caspase activation, and caspase-dependent and -independent components of the mitochondrial cell death pathway. A balance
between these intracellular signaling pathways determines whether cells will die or survive after exposure to TNF-a. TNFa-
mediated ROS generation is mainly derived from mitochondria and membrane-associated NADPH oxidase, which con-
tributes to signaling pathways. JNK, c-Jun N-terminal Kinase.
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by inhibiting TNF-a-mediated NF-jB activity, resulting in bcl-
2 protein downregulation (33). There is a caveat to targeting
TNF-a in prostate cancer therapy. TNF-a synergizes with c-
irradiation to induce apoptosis in LNCaP cells through a
mechanism that may involve increased production of cer-
amide at 48–72 h after exposure (91). Anti-TNF-a treatment
may mitigate the effect of c-irradiation. Depending on TNF-a
dose and prostate cancer cell type, different isoforms of C/
EBPb may regulate cell growth and confer TNF-a resistance to
prostate cancer cells (89). Although TNF-a is clearly linked
with prostate cancer progression and radioresistance, it may
also contribute to tumor immune surveillance and apoptosis-
mediated antitumor pathways. Since TNF-a expression is
subjected to redox regulation, the difference between tumor
and normal cells in their redox regulation and adaptive redox
buffering capacity can be exploited to shift the paradoxical
effects TNF-a toward increased immune surveillance and
tumor cell apoptosis.
Transforming growth factor-beta
TGF-b is a ubiquitous cytokine that plays a critical role in
numerous pathways regulating homeostasis and injury re-
sponse as well as in the progression of human cancer. Prior to
tumor initiation and during early phases of tumor progres-
sion, TGF-b acts as a tumor suppressor. At later stages of
cancer development, TGF-b promotes processes associated
with tumor aggressiveness, such as cell invasion, dissemina-
tion, and immune invasion (48, 114). In mammals, there are
three TGF-b isoforms: TGF-b1, TGF-b2, and TGF-b3. With the
assistance of the coreceptors endoglin and betaglycan (known
as type III receptors or TGFbRIII), active TGF-b binds to cell
surface type I (TGFbRI) and type II (TGFbRII) serine/threo-
nine kinase receptors, which phosphorylate and activate the
Smad family of signal transducers (48) (Fig. 7).
Once activated by TGF-b binding to the receptors, Smad2
and Smad3 associate with Smad4 and translocate to the nu-
cleus where they regulate the transcription of genes involved
in cell cycle arrest and apoptosis, which are essential to the
tumor suppressor role of the TGF-bs in normal epithelial cells
and at early stages of carcinogenesis (18, 19). TGF-b-induced
growth arrest is mediated by the inhibition of cyclin-depen-
dent kinases and the downregulation of myelocytomatosis
oncogene cellular homolog [reviewed in (48)]. Mutational
inactivation of TGF-b signal-transduction components, such
as the TGF-b type II receptor (TGFbRII) (60) or its mediators,
Smad2 and Smad4, leads to defective TGF-b signaling in some
cancers (17, 59). Pu et al. developed a transgenic adenocarci-
noma of mouse prostate-based prostate cancer transgenic
mouse model that harbors the dominant negative mutant
TGF-b type II receptor in epithelial cells to characterize the
in vivo consequences of inactivated TGF-b signaling on prostate
tumor initiation and progression, and found that disruption of
TGF-b signaling in vivo accelerated pathologic malignant
changes in the prostate by altering the kinetics of prostate
growth and inducing EMT (143). These findings indicate that
TGF-b exerts its tumor suppressor functions through inhibition
of cell proliferation, induction of apoptosis, and regulation of
autophagy.
TGF-b is expressed at high levels in the later stages of tumor
development (192), during which it is utilized as a potent
promoter of cell motility, invasion, metastasis, and tumor
stem cell maintenance, as demonstrated in experimental
prostate cancer models (121). Local TGF-b1 elevation has been
associated with tumor grade, pathologic stage, and lymph
node metastasis in prostate cancer patients (162). Although
some investigators were not able to find a discriminative
difference in the serum concentration of TGF-b1 in benign
prostate hyperplasia and prostate cancer (195), elevated levels
of plasma TGF-b1 (77), TGF-b2 (139), and urinary TGF-b1
(139) were found in patients with prostate cancer.
TGF-b1 plays a critical role in tumor–stromal cell interac-
tions and modulates the growth of prostate cancer, either
positively or negatively, through the balance between the
amounts of IGF-1 and IGF binding protein-3 (85). Resistance
to TGF-b-mediated growth arrest results in highly malignant
phenotypes with increased EMT, tumor invasion, metastatic
dissemination, and evasion of immune surveillance (114).
Interestingly, TGF-b1 activates IL-6, which has been impli-
cated in the malignant progression of prostate cancers, as
described earlier, via multiple signaling pathways, including
Smad2, NF-jB, JNK, and Ras (136). Zhu and Kyprianou have
provided a detailed description of the crosstalk between AR
and growth factors, including TGF-b-mediated signaling
pathways, in prostate cancer cells (203). Smad3, a down-
stream mediator of the TGF-b signaling pathway, can func-
tion as a coregulator to enhance AR-mediated transactivation
and increase AR-targeted PSA gene expression (82). Con-
sidering the correlation between increased circulating levels
of TGF-b1 with invasion (77), metastasis (77), and poor
prognosis in patients with prostate cancer (162), TGF-b1 could
be an additional serum marker for prostate cancer (16, 176).
FIG. 7. TGF-b-mediated classical Smads signaling path-
way. With the assistance of TGFbRIII, active TGF-b (three
isoforms, i.e., TGF-b1, TGF-b2, and TGF-b3) binds to cell
surface TGFbRI and TGFbRII, which phosphorylate and ac-
tivate the Smad family of signal transducers.
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TGF-b acts as an important mediator for response to IR, and
its signaling is tightly regulated by redox status within tumor
cells and the tumor microenvironment. IR has been shown to
induce the release and activation of TGF-b in cells and tissues
(13). A mechanistic study in a cell-free system demonstrated
that oxidation of the TGF-b latent complex acts as a sensor of
oxidative stress to mediate the release and activation of TGF-
b1 and orchestrate cellular responses to damage (12). More
aspects of TGF-b biology, particularly its involvement in the
microenvironmental response to IR, have been described el-
egantly (13). Intracellular redox equilibrium is essential for
constitutive AP-1-dependent TGF-b1 expression (57). Nitric
oxide downregulates TGF-b1 expression in prostate cancer
cells at the transcriptional level by suppressing the de novo
synthesis of TGF-b1 mRNA (188). TGF-b1 induces a stromal
oxidant/antioxidant imbalance as a result of elevated NOX4-
dependent ROS production and inhibits the expression of the
MnSOD and catalase (116) that may be critical in the acqui-
sition of epithelial migratory properties (23). In addition,
TGF-b1 decreases ETC complex IV activity by decreasing
phosphorylation of the subunit 6b of glycogen synthase
kinase 3, which contributes to senescence-associated mito-
chondrial ROS generation (28). The significant roles of TGF-b
in modulating tumor intracellular and extracellular redox
statuses suggest that TGF-b signaling is involved in mediating
cell autonomous, local, and systemic responses, which to-
gether regulate the initiation, promotion, progression, and
prognosis of prostate cancer.
Radiotherapy-induced TGF-b activation may have unde-
sirable side effects that are implicated in late tissue damage,
such as fibrosis (6, 108). Several studies support the use of
TGF-b inhibitors to ameliorate IR toxicity to normal tissues
(51, 146). Anticancer therapies, such as IR or doxorubicin,
may accelerate the steps of tumor progression, such as EMT
and metastasis, due to the promoting effect of TGF-b within
the tumor microenvironment (4, 130). This effect can be ab-
rogated by administration of a pan-TGF-b neutralizing an-
tibody (19). Current strategies to target TGF-b in
radiotherapy mainly focus on general inhibition of TGF-b
signaling. It has been shown that blockade of TGF-b signal-
ing prior to irradiation attenuates DNA damage responses,
increases clonogenic cell death, and promotes tumor growth
delay and, thus, enhances radiation response and prolonged
survival in patients with breast cancer (24) and glioblastoma
(68), but renders a lung cancer cell line more radioresistant
(191). Genetic differences and tumor specificity can be im-
portant factors in determining the radiosensitizing effect of
TGF-b inhibition in radiotherapy. For an example, a hypo-
functional genetic haplotype of the TGFB1 gene encoding
TGF-b1 is associated with lower TGF-b1 plasma concentra-
tions and increased sensitivity to radiation-induced chro-
mosomal aberrations and apoptosis in lymphoid cells (155).
There are three major approaches to inhibit TGF-b signaling:
targeting TGF-b synthesis using antisense molecules and
using ligand traps that sequester TGF-b and small-molecule
inhibitors that hinder the kinase activity of TGF-b receptors
[reviewed in (5, 114)]. Since IR-induced TGF-b may not only
provide a survival benefit to cancer cells that are radio-
resistant but also accelerate tumor progression, targeted
disruption of the TGF-b signaling pathway for therapeutic
intervention may be an effective adjuvant in cancer radio-
therapy.
Conclusion and Future Perspectives
Radiation therapy is generally used to treat early stage and
inoperable locally advanced prostate cancer. Radiation kills
prostate cancer cells and extends long-term patient survival
by direct and indirect actions leading to macromolecule
damages and altered redox signaling. However, IR is also
responsible for the induction of neoplastic transformation and
tumor progression as well as normal tissue injuries. The de-
velopment of radioresistance is a significant impediment to
prostate cancer treatment. The side effects and late compli-
cations that result from IR exposure limit the full potential of
radiotherapy efficacy. Considering the heterogeneity of tu-
mors, dynamic communications between stromal and pros-
tate cancer cells as well as the complicated redox-regulated
mechanisms within the tumor microenvironment—simply
applying generalized anti-inflammatory strategies—might
result in unintended adverse effects. Thus, it is important to
develop individualized treatment regimes that will be most
effective and will not disrupt antitumor immunity in indi-
vidual patients. Additionally, redox-dependent proin-
flammatory mediator production from the directly exposed
cells and their neighboring nonirradiated cells, as the by-
stander effect of radiotherapy, may play a critical role in the
response of cells and tissues to IR. The key roles of IR-induced
cytokines and growth factors and their interference with
prostate cancer radiotherapy have been extensively discussed
in this review with an emphasis on IL-6, IL-8, TNF-a, and
TGF-b. These major cytokines, which are induced by IR in
prostate cancer treatment, are not only involved in modulat-
ing redox balance but are also subjected to regulation by
various oxidative stresses. Compared and contrasted to nor-
mal cells, tumor cells are usually under a higher oxidative
stress and secrete more proinflammatory mediators. An in-
cremental increase in oxidative stress to the extent that is still
within the adaptive redox buffering capability of normal cells
may overwhelm the less adaptive redox buffering capability
of cancer cells, thereby selectively disrupting the redox state in
tumor cells and activating the apoptotic or necrotic pathway,
which leads to selective killing of tumor cells. Thus, modu-
lation of IR-induced oxidative stress and inflammatory cyto-
kine signaling may provide a better basis for enhancing
radiation-mediated killing in prostate cancer treatment with
minimal normal tissue damage.
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Abbreviations Used
2-ME¼ 2-methoxyestradiol
3DCRT¼ 3-dimensional conformal radiation therapy
AP-1¼ activator protein-1
APE1¼AP endonuclease 1
AP site¼ abasic site
AR¼ androgen receptor
ATF¼ activating transcription factor
BER¼ base excision repair
CAF¼ cancer associated fibroblast
COX-2¼ cyclooxygenase-2
CREB¼ cAMP response element binding protein
Cu/ZnSOD¼ copper/zinc superoxide dismutase
DEP-1¼density-enhanced protein tyrosine
phosphatase-1
ECSOD¼ extracellular superoxide dismutase
EGF¼ epidermal growth factor
EGFR¼ epidermal growth factor receptor
EMT¼ epithelial mesenchymal transition
ETC¼mitochondrial electron transport chain
FGF¼fibroblast growth factor
GPx¼ glutathione peroxidase
GR¼ glutathione reductase
Grx¼ glutaredoxin
GSH¼ glutathione
GST¼ glutathione S-transferase
HIF-1a¼hypoxia-inducible factor-1alpha
HO-1¼heme oxygenase-1
IGF¼ insulin-like type I growth factor
IGF-1R¼ insulin-like type I growth factor receptor
IL-1b¼ interleukin-1beta
IL-6¼ interleukin-6
IL-8¼ interleukin-8
IR¼ ionizing radiation
Jak¼ Janus kinase
JNK¼ c-Jun N-terminal kinase
LPX¼ lipoxygenase
MAPK¼mitogen-activated protein kinase
MnSOD¼manganese superoxide dismutase
mtDNA¼mitochondrial DNA
MYC¼myelocytomatosis oncogene cellular
homolog
NE¼neuroendocrine
NED¼neuroendocrine differentiation
NF-jB¼nuclear factor kappa B
NOX¼NADPH oxidase
PPARc¼peroxisome proliferator-activated receptor
gamma
PI3K¼phosphatidyl inositol 3-kinase
PIA¼proliferative inflammatory atrophy
PIAS¼protein inhibitors of activated STATs
Prx¼peroxiredoxin
PSA¼prostate-specific antigen
PTP¼protein tyrosine phosphatase
Rac1¼ ras-related C3 botulinum toxin substrate 1
RIP1¼ receptor Interacting Protein 1
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
SH2¼ Src-homology 2
sIL-6R¼ soluble IL-6 receptor
SOD¼ superoxide dismutase
STAT¼ signal transducers and activators
of transcription
TACE¼TNF-converting enzyme
TAM¼ tumor-associated macrophage
TGF-b¼ transforming growth factor-beta
TNAF4¼TNF-a receptor-associated factor 4
TNF-a¼ tumor necrosis factor-alpha
TNFRI¼TNF-receptor I
TRAIL¼TNF-related apoptosis-inducing ligand
TRAMP¼ transgenic adenocarcinoma of mouse prostate
Trx¼ thioredoxin
TRXox¼ oxidized thioredoxin
TrxR¼ thioredoxin reductase
TRXre¼ reduced thioredoxin
VEGF¼vascular endothelial growth factor
VEGFR2¼vascular endothelial growth factor
receptor 2
XO¼ xanthine oxidase
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